Literature DB >> 23052341

[Chronic inflammatory bowel diseases. Clinical aspects and new therapy approaches].

B Siegmund1.   

Abstract

There is a continuously increasing incidence in inflammatory bowel diseases affecting mostly young people who are in a vulnerable phase of life. Thus, early diagnosis and initiation of an effective therapeutic regimen is critical in order to maintain a good quality of life. In Germany, the standard therapeutic strategy is an accelerated step up approach, including the introduction of early immunosuppressive therapy if required. Although novel therapeutic strategies have found their way into clinical use there is still a substantial subgroup of patients where effective therapy is lacking. The future introduction of anti-adhesion molecule antibodies might provide a realistic option for this subgroup. Equally important is the availability of predictive markers allowing stratification of patients into subgroups at the time of diagnosis. Assuming that the CD8(+) T cell transcriptome approach will be confirmed in prospective trials, personalized therapy in patients with inflammatory bowel disease will be the next step.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23052341     DOI: 10.1007/s00292-012-1641-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  19 in total

1.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

2.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

3.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

4.  Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.

Authors:  Cynthia H Seow; Joanne M Stempak; Wei Xu; Hui Lan; Anne M Griffiths; Gordon R Greenberg; A Hillary Steinhart; Nir Dotan; Mark S Silverberg
Journal:  Am J Gastroenterol       Date:  2009-04-21       Impact factor: 10.864

5.  [Clinical practice guideline on diagnosis and treatment of Crohn's disease].

Authors:  J C Hoffmann; J C Preiss; F Autschbach; H J Buhr; W Häuser; K Herrlinger; W Höhne; S Koletzko; C F Krieglstein; W Kruis; H Matthes; G Moser; M Reinshagen; G Rogler; S Schreiber; A G Schreyer; B Sido; B Siegmund; A Stallmach; B Bokemeyer; E F Stange; M Zeitz
Journal:  Z Gastroenterol       Date:  2008-09-22       Impact factor: 2.000

6.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Authors:  Edouard Louis; Jean-Yves Mary; Gwenola Vernier-Massouille; Jean-Charles Grimaud; Yoram Bouhnik; David Laharie; Jean-Louis Dupas; Hélène Pillant; Laurence Picon; Michel Veyrac; Mathurin Flamant; Guillaume Savoye; Raymond Jian; Martine Devos; Raphaël Porcher; Gilles Paintaud; Eric Piver; Jean-Frédéric Colombel; Marc Lemann
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

7.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

8.  Predictors of Crohn's disease.

Authors:  Laurent Beaugerie; Philippe Seksik; Isabelle Nion-Larmurier; Jean-Pierre Gendre; Jacques Cosnes
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

9.  Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.

Authors:  James C Lee; Paul A Lyons; Eoin F McKinney; John M Sowerby; Edward J Carr; Francesca Bredin; Hannah M Rickman; Huzefa Ratlamwala; Alexander Hatton; Tim F Rayner; Miles Parkes; Kenneth G C Smith
Journal:  J Clin Invest       Date:  2011-09-26       Impact factor: 14.808

10.  A CD8+ T cell transcription signature predicts prognosis in autoimmune disease.

Authors:  Eoin F McKinney; Paul A Lyons; Edward J Carr; Jane L Hollis; David R W Jayne; Lisa C Willcocks; Maria Koukoulaki; Alvis Brazma; Vojislav Jovanovic; D Michael Kemeny; Andrew J Pollard; Paul A Macary; Afzal N Chaudhry; Kenneth G C Smith
Journal:  Nat Med       Date:  2010-04-18       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.